On the other hand, KRAS mutations are observed in approximately 90% of pancreatic cancer patients, and mutations in tumor suppressors such as CDKN2A/p16INK4A, Trp53, and SMAD4 are also common in pancreatic cancer. Here, KRAS is linked to neoplasm.